TY - JOUR T1 - SCO-267, a GPR40 full agonist, improves glycemic and body weight control in rat models of diabetes and obesity JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.118.255885 SP - jpet.118.255885 AU - Hikaru Ueno AU - Ryo Ito AU - Shin-Ichi Abe AU - Mitsugi Ookawara AU - Hirohisa Miyashita AU - Hitomi Ogino AU - Yasufumi Miyamoto AU - Tomoki Yoshihara AU - Akihiro Kobayashi AU - Yoshiyuki Tsujihata AU - Koji Takeuchi AU - Masanori Watanabe AU - Yukio Yamada AU - Tsuyoshi Maekawa AU - Nobuhiro Nishigaki AU - Yusuke Moritoh Y1 - 2019/01/01 UR - http://jpet.aspetjournals.org/content/early/2019/06/11/jpet.118.255885.abstract N2 - GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of SCO-267, a novel full agonist of GPR40. Ca2+ signaling and insulin and glucagon-like peptide-1 (GLP-1) secretion were evaluated in GPR40-expressing CHO, MIN6, and GLUTag cells. Hormone secretions and effects on fasting glucose were tested in rats. Single or repeated dosing effects were evaluated in N-STZ-1.5 rats, diet-induced obese (DIO) rats, and GPR40-knockout (Ffar1-/-) mice. Treatment with SCO-267 activated Gq signaling in both high- and low-FFAR1-expressing CHO cells, stimulated insulin secretion in MIN6 cells, and induced GLP-1 release in GLUTag cells. When administered to normal rats, SCO-267 increased insulin, glucagon, GLP-1, glucose-dependent insulinotropic peptide, and peptide YY (PYY) secretions under non-fasting conditions. These results show the full agonistic property of SCO-267 against GPR40. Hypoglycemia was not induced in SCO-267-treated rats during the fasting condition. In diabetic N-STZ-1.5 rats, SCO-267 was highly effective in improving glucose tolerance in single and 2-week dosing studies. DIO rats treated with SCO-267 for 2 weeks showed elevated plasma GLP-1 and PYY levels, reduced food intake, and decreased body weight. In wild-type mice, SCO-267 induced GLP-1 secretion, food intake inhibition, and body weight reduction; however, these effects were abolished in Ffar1-/- mice, indicating a GPR40-dependent mechanism. In conclusion, SCO-267 stimulated islet and gut hormone secretion, improved glycemic control in diabetic rats, and decreased body weight in obese rats. These data suggest the therapeutic potential of SCO-267 for the treatment of diabetes and obesity. ER -